Buntanetap, which inhibits the translation of neurotoxic proteins such as α-synuclein, may hold more promise, and has recently been demonstrated to improve motor scores and lower levels of α-synuclein in the CSF in a small cohort of early-PD patients (clinical-trial identifier NCT04524351) [131]. This evidence concerns the gene SNCA and Parkinson disease.